位置:首页 > 产品库 > Riociguat-13C-d3
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Riociguat-13C-d3
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Riociguat-13C-d3图片
规格:98%
分子量:426.4
包装与价格:
包装价格(元)
500ug询价
1mg询价

A neuropeptide with diverse biological activities
货号:ajcx23436
CAS:N/A
分子式:C19[13C]H16D3FN8O2
分子量:426.4
溶解度:DMF: 10 mg/ml,DMSO: 10 mg/ml
纯度:98%
存储:Store at -20°C
库存:现货

Background:

Riociguat-13C-d3is intended for use as an internal standard for the quantification of riociguat by GC- or LC-MS. Riociguat is a stimulator of soluble guanylate cyclase (sGC).1,2It stimulates recombinant sGC in a concentration-dependent mannerin vitroby up to 73-fold when used at a concentration of 100 μM and by up to 112-fold when used in combination with the nitric oxide (NO) donor DEA NONOate .1It has no effect on phosphodiesterases PDE1-9 and PDE11 when used at concentrations up to 3 μM. Riociguat (1 and 10 mg/kg) reduces pulmonary and systemic arterial pressure in a rabbit model of acute pulmonary arterial hypertension (PAH) induced by U-46619 . It also inhibits increases in right ventricular systolic pressure, right heart hypertrophy, and pulmonary artery muscularization in hypoxia-induced mouse and monocrotaline-injected rat models of chronic PAH when administered at a dose of 10 mg/kg. Formulations containing riociguat have been used in the treatment of chronic thromboembolic pulmonary hypertension (CTEPH) and PAH.


1.Schermuly, R.T., Stasch, J.P., Pullamsetti, S.S., et al.Expression and function of soluble guanylate cyclase in pulmonary arterial hypertensionEur. Respir. J.32(4)881-891(2008) 2.Stasch, J.P., Pacher, P., and Evgenov, O.V.Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary diseaseCirculation123(20)2263-2273(2011)

 
 
维奥蛋白资源库 - 中文蛋白资源 CopyRight © 2010-2024